
The fund's primary objective is to achieve long-term capital appreciation. To meet this goal, it typically invests at least 80% of its net assets (including any assets acquired through borrowing) in the common stocks of companies within the broad "health sciences" sector. This includes firms involved in the research, development, production, or distribution of products and services related to healthcare, medicine, or life sciences. While the fund maintains the flexibility to invest in companies of any size, the majority of its portfolio is expected to be allocated to large- and mid-capitalization companies.
Is THISX's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
No recent news available.